Indene derivatives useful in treating pain and inflammation
Inventors
Harwig, Curtis • PETTIGREW, Jeremy D. • Cross, Jennifer • Seenisamy, Jeyaprakashnarayanan • Keregadde, Mahesh Narayan • IYANAR, Karthikeyan
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11773108-B2
Publication Date
2023-10-03
Expiration Date
Abstract
Compounds of formula (1): wherein, R1, R2, R3, R4a, R4b and R5 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds are useful in treating inflammation and/or pain. Compositions comprising a compound of the invention are also disclosed, as are methods of using the compounds to treat inflammation and/or pain.
Core Innovation
The invention is directed to administering a therapeutically effective amount of a pharmaceutical composition comprising a compound of formula (I), or a stereoisomer, enantiomer, tautomer, or mixtures thereof, and pharmaceutically acceptable salts or solvates thereof, to a mammal in need. The method treats inflammation and/or pain caused by colitis, cystitis, chronic prostatitis or chronic pelvic pain, osteoarthritis, inflammatory pain, hyperalgesia, neuropathic pain, and/or pulmonary inflammation or fibrosis.
Formula (I) includes an optionally substituted fused 5- or 6-membered N-heteroaryl, including fused pyrazolyl arrangements, with substituent variables R1 through R9 and R10 through R11. R1 is hydrogen, R2 and R3 are selected from —R6—OR7 and —R6—N(R8)2, and R4a and R4b define options including alkylidene formation or a bond to C16, while R4 and R1 together form an optionally substituted bicyclic heterocyclyl.
Additional structural definitions specify substituted aryl, substituted aralkyl, substituted cycloalkyl, or substituted heteroaryl options, with R5 as alkyl or a direct bond to the carbon at C14. R6 is independently a direct bond or a straight or branched alkylene chain, and R7 and R8 are independently hydrogen or alkyl.
Claims Coverage
The independent claim is directed to a method of treating inflammation and/or pain by administering a therapeutically effective amount of a pharmaceutical composition containing a compound of formula (I). Two inventive features are identifiable: the treatment method and the detailed structural definition of formula (I), including the fused optionally substituted N-heteroaryl core and substituent constraints.
Treating specified inflammation and/or pain by administering formula (I) compounds
A method of treating inflammation and/or pain caused by colitis, cystitis, chronic prostatitis or chronic pelvic pain, osteoarthritis, inflammatory pain, hyperalgesia, neuropathic pain, and/or pulmonary inflammation or fibrosis, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound of formula (I), including stereoisomers, enantiomers, tautomers, mixtures thereof, and pharmaceutically acceptable salts or solvates thereof, to a mammal in need thereof.
Optionally substituted fused 5- or 6-membered N-heteroaryl core with defined substituent variables
Formula (I) is defined by an optionally substituted fused 5- or 6-membered N-heteroaryl, including fused pyrazolyl arrangements, with R1 as hydrogen; R2 and R3 as —R6—OR7 or —R6—N(R8)2; R4a and R4b options including alkylidene formation or an optionally substituted aryl with a bond to C16, or alkyl with R4b as hydrogen; R4 and R1 together forming an optionally substituted bicyclic heterocyclyl; and R5, R6, R7, R8, R9, R10, and R11 defined by the stated bond, alkylene, hydrogen, alkyl, and substitution selections.
Overall, the claim coverage centers on administering a therapeutically effective amount of a pharmaceutical composition containing a compound of formula (I) for treating specified inflammation and/or pain disorders in a mammal. The inventive scope is defined by the fused 5- or 6-membered N-heteroaryl core and the explicit R-group and bonding constraints, together with stereoisomer, enantiomer, tautomer, salt, and solvate options.
Stated Advantages
Documented Applications
Treating inflammation and/or pain caused by colitis.
Treating inflammation and/or pain caused by cystitis.
Treating inflammation and/or pain caused by chronic prostatitis or chronic pelvic pain.
Treating inflammation and/or pain caused by osteoarthritis.
Treating inflammatory pain, hyperalgesia, and neuropathic pain.
Treating pulmonary inflammation or fibrosis.
Interested in licensing this patent?